Dr Kate Mahon
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
- 2023Prostate cancer and prostatic diseases10.1038/s41391-023-00666-2
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer.
- 2022BMC medicine10.1186/s12916-022-02298-0
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
- 2021JCO precision oncology10.1200/PO.20.00424
Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.
- 2020European urology10.1016/j.eururo.2020.03.044
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.